Atias Pharma, LLC

About

Atias Pharma combines insights derived from the physiology and pathophysiology of targets with a deep molecular understanding of target ligand-receptor interactions to enable novel drug discovery, with initial focus on endocrine fibroblast growth factor 21 (FGF21). Our lead development programs are for the acute treatments of acute pancreatitis, acute alcohol overdose, and a subset of hepatocellular carcinoma, with potent FGF21 variants tailored for each indication.